Power Law company profile

UniQure

Biotech & Life Sciences · Amsterdam, Netherlands · Founded 1998 · IPO 2014 Unicorn

Delivering on the promise of gene therapy - single treatments with potentially curative result for patients with severe genetic diseases.

Valuation

$698M

Market cap · May/2026

Revenue

$16M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on UniQure's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 5 investors entered at this stage

Chiesi Pharmaceuticals

Amsterdam UMC

University of Amsterdam

Forbion Capital Partners

Coller Capital

UniQure mafia

Startups founded by UniQure alumni

Former UniQure employees who went on to start their own companies. Sorted by Dealroom signal score.

VectorY TherapeuticsEst. 2020

PKPavlina Konstantinova,Netherlands

Signal score86

Fuse VectorsEst. 2022

Benjamin BlahaDenmark

Signal score70

Frontera TherapeuticsEst. 2019

Yong DaiUnited States

Signal score65

Cardior PharmaceuticalsEst. 2016

Claudia UlbrichGermany

Signal score65

SalioGen TherapeuticsEst. 2020

Joseph J. HigginsUnited States

Signal score61

Synerkine PharmaEst. 2018

HPHans PreustingNetherlands

Signal score59

G7 TherapeuticsEst. 2013

Jörn AldagSwitzerland

Signal score56

HypherdataEst. 2019

JMJana MiniarikovaNetherlands

Signal score53

Book a demo to explore the full alumni network →

Global footprint

Where UniQure has talent and traffic

AI talent share

1.3% of workforce is AI talent
(4 of 313 staff)

Core AI10.32%

Other AI30.96%

Non-AI workforce30998.72%

Workforce by country

8 countries with
team presence

🇳🇱 Netherlands53.3%

🇺🇸 United States40.7%

🇨🇭 Switzerland3.9%

🇬🇧 United Kingdom0.6%

🇩🇪 Germany0.4%

Top 5 of 8 shown

Web traffic by country

36K monthly visits
across markets

🇺🇸 United States32.8%

🇨🇦 Canada11.7%

🇳🇱 Netherlands9.7%

🏳️ Korea8.3%

🏳️ Republic of6.9%

Top 5 markets shown

Patent intelligence

$58M patent portfolio · 22 active families

Estimated portfolio value

$58M

8.3% of market cap · 13.5× smaller than top peer BioNTech ($780M)

22 active patent families

Where UniQure innovates Molecular biologyCell biologyParvovirusNucleotide sequencingRibosomal RNA Genes

Where UniQure concentrates vs peers

Each axis is a top-10 topic across UniQure and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about UniQure

An AI-synthesized read of the highest-engagement posts about UniQure on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See UniQure on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles